Clinical Trial Update: Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating first-line anti-PD-1/PD-L1 monoclonal antibody plus chemotherapy with bronchoscopy-assisted interventional therapy in advanced centra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Advanced Lung Carcinoma, Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN